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1 ABSTRACT 
 Brain injury during the neonatal period has potentially lifelong 
consequences for a child. Perinatal infections and inflammation can induce preterm 
birth and unfavorable cognitive development, Thus inflammation has received 
enthusiastic interest for potential therapeutic approaches seeking to protect the newborn 
brain. Experimental evidence demonstrates that inflammation induces brain injury 
succeeding the initial insult. A key cytokine in brain injury is the tumor necrosis factor 
TNFα), with reported detrimental cytotoxic effects on selected neuronal populations. 
Nonetheless, important functions of TNFα in cerebral homeostasis and development 
have also been described. Caffeine is used against apneas of prematurity, with 
noticeable protection against cognitive delay and cerebral palsy. The main effects of 
caffeine at clinically relevant doses are mediated through inhibition of adenosine 
receptors. Adenosine is formed from adenosine triphosphate, the main transporter of 
chemical energy in the cell, which is readily cleaved to adenosine upon extracellular 
release or extensive leakage from injured necrotic cells. Hence, adenosine signaling is 
tightly interrelated with local energy levels and cell injury. In addition, adenosine 
modulates inflammatory responses in profound ways. 
 In mouse models of premature excitotoxic lesions and full term hypoxic 
ischemic brain injury we investigated blockade of TNFα with and without interleukin
1 I1) or lipopolysaccharide P) induced systemic inflammation. Furthermore, in 
the hypoxic ischemic model we developed a flow cytometry based method to 
investigate temporal distribution of brain infiltrating and splenetic immune cells and 
their activation. To analyze the data in an unbiased way, we next adapted a data driven 
gating methodology. Moreover, we used principal component analysis to discriminate 
between experimentally entangled variables. Utilizing these techniques, we explored 
the effect of genetic inactivation of adenosine A1 and A2A receptors in the hypoxic 
ischemic model. We also tested the unselective, competitive adenosine receptor 
antagonist caffeine and assessed the effect on outcome and immune activation. 
 Blockade of TNFα protected the brain against excitotoxic lesions in the 
presence but not absence of systemic inflammation. No protection was observed in the 
full term hypoxic ischemic model. Persistent lymphocyte activation was found three 
months after the lesion. Moreover, spleenocytes harvested five months after neonatal 
brain damage proliferated when stimulated with brain homogenate in contrast to sham 
operated counterparts. Adenosine A1 receptor deficient mice acquired significantly 
larger infarcts and associated adverse behavioral outcome compared to wild type. There 
were specific alterations in the immune responses induced after brain injury, including 
impaired cytotoxic function and dysregulation of regulatory Blymphocytes. Adenosine 
A2A receptor knockout mice developed increased atrophy compared to wild type after 
hypoxic ischemia, an effect accompanied by functional deficits in behavioral tests. 
Furthermore, a compensated functional insufficiency was estimated in the regulatory T
lymphocyte compartment in combination with a seemingly inadequate number of 
myeloid derived suppressor like cells, accompanied by a reversed, increased response 
in innate antigen presenting cells in the knockout. Finally, we report neuroprotective 
properties of 5 mg/kg caffeine given directly after neonatal brain injury. 
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 TFα blockade could potentially protect against preterm excitotoxic 
brain injury. Only patients with concurrent systemic inflammation would potentially 
benefit. oreover, concern about adverse effects exists, why TFα blockade for 
neonatal brain injury is likely not clinically applicable in the near future. 
Persistent long term cerebral adaptive immune activation, preceded by systemic 
immune activation in spleen was discovered. Remarkably, spleenocytes from animals 
subjected to brain injury responded to brain antigen five months after brain damage, 
whereas spleenocytes from uninjured did not, suggesting formation of immunological 
memory that might affect long term outcome and provoke autoimmunity later in life. 
To avoid bias from manual gating of flow cytometry data we developed a data driven 
approach adapted for brain infiltrating immune cells. Furthermore, we deployed 
principal component analysis to verify biological relevance in the pattern of immune 
activation and to discriminate between genotype and injury size effects, since they are 
experimentally inseparable. Thus we could predict genotype and whether they acquired 
brain injury or not, from the flow cytometric immune activation pattern alone. 
Adenosine A1 receptor deficient mice display signs of regulatory lymphocyte 
dysfunction that imply a novel adenosinergic mechanism of lymphocyte regulation. 
In addition, these animals displayed signs of altered cellular cytotoxic immunity. Thus 
considerable effects on immune activation were present in the A1 receptor knockouts 
compared to wild type, adding another mechanism linked to worse outcome after 
hypoxic ischemic brain injury in these animals. 
Deletion of the adenosine A2A receptor similarly causes worse outcome, however, the 
alteration of the immune response is completely different. Fundamental changes were 
observed in regulatory populations like monocyte derived suppressor like cells and 
regulatory Tlymphocytes. xtensive activation of cytotoxic populations in the 
adenosine A2A receptor knockout links insufficient regulatory immune function with 
adverse behavioral and morphological outcome. 
We also propose a novel hypothesis that short term blockade of adenosine A2A 
receptors offers neuroprotection whereas long term blockade is detrimental by 
immunological mechanisms. Thus we tested the tentative therapeutic potential of 
caffeine, an unselective competitive antagonist of adenosine receptors. Caffeine 
5mg/kg given directly after the insult resulted in reduced injury size after neonatal 
hypoxic ischemia. Since caffeine is a relatively well studied substance with negligible 
adverse long term effect in technically sound studies absent of significant bias, this 
approach has a clear clinical relevance. Are we ready for a clinical trial? 
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5 BACKGROUND 
Brain injury in the newborn child is a tragedy with potentially lifelong consequences. 
Injury to the developing brain inflicts disturbance not only to neuronal function, but 
growth and organization of the immature brain is impaired as well. Hence, 
developmental age is essential to the brain pathology seen (Inder and Volpe 2000). 
Premature children born during week 2432 are predisposed to acquire white matter 
damage, since preoligodendrocytes mature to myelinate the neurons during this 
developmental period (Hagberg, Peebles et al. 2002). Immature oligodendrocytes are 
particularly susceptible to the reactive oxygen species formation that occurs during 
ischemia, whereas mature oligodendrocytes are more resistant to oxidative stress 
(Ferriero 2004). Periventricular hemorrhage provoking venous congestion and 
subsequent ischemia (Inder and Volpe 2000) is also quite common in premature babies, 
possibly due to immature vascular beds. Maternal or fetal inflammation is associated 
with preterm delivery that in itself hamper brain development and it has been proposed 
that infection could even cause direct cognitive deterioration (Dammann, Kuban et al. 
2002). A current metaanalysis of neurodevelopmental outcome now conclude that 
perinatal infections influence outcome adversely (van Vliet, de Kieviet et al. 2013). 
Thus, inflammatory mediators are implicated in the pathogenesis of preterm brain 
injury, an hypothesis supported by accumulating human and experimental data (Volpe 
2001). 
However, in full term neonates selected populations of neurons are the cells most 
susceptible to harm, typically resulting in grey matter injury (Ferriero 2004). Asphyxia 
induced hypoxic ischemia (HI) is the major cause of neonatal brain injury in full term 
babies and the incidence of moderate to severe hypoxic ischemic encephalophathy is 
0.2 per 1000 live births in the developed world (Kurinczuk, hiteKoning et al. 
2010) and much more common in low income countries (Costello and Manandhar 
1994). There is hope though, since many neonates with brain injury have a brain 
function similar to uninjured children, illustrating the inherited inspiring regenerative 
capacity and plasticity of the neonatal brain (Ballantyne, Spilkin et al. 2008). 
Furthermore, prognosis and survival after neonatal brain injury has improved due to 
better postnatal care with moderate cooling as the only specific treatment for neonatal 
hypoxic ischemic encephalopathy (Jacobs, Hunt et al. 2007). Major improvements have 
been achieved through the development of neonatal intensive care, with enhanced 
treatment of respiratory distress, sepsis, chock and use of drugs specifically adapted for 
neonates (Ferriero 2004). Improved obstetric care, nutrition, special consideration for 
premature infants and continuous support during the entire childhood are additional 
positive influencing factors (Luciana 2003). 
 8 
5.1 INFLAMMATION 
Tissue damage and disruption of cellular integrity releases intracellular molecules 
that act as danger signals, which trigger an immune response to combat destr
substances have immunogenic properties and
If no infection is present, they initiate an aseptic inflammation after brain injury, breach
immune infiltration and secondary injury. When one contemplates this model, it is 
infectious or inflammatory agent can aggravate the injury.
Inflammation has been identified as a key factor for
after asphyxia (Hagberg, Gressens et al. 2012
physiological conditions the blood b
therefore the brain is considered an immunopr
2007). However, the brain possesses other immunological mechanisms to 
against harm, where both resident microglia and astrocytic cells 
elicit immune responses (McRae, Gilland et al. 1995
5.1.1 Inflammation after brain injury
 
Hypoxic ischemia causes an imbalance 
when oxygen and nutrient supplies are insufficient. If energy failure is se
brain cells cannot handle the stress and die. The modes of cell death can theoretically 
be divided into controlled apoptosis and unrestrained necros
2012). Apoptosis is an orchestrated energy dependent process that can be induced both 
intrinsically due to DNA damage or
death signals, causing negligible effects on extracellul
Rousset et al. 2012). In contrast, necrosis causes disruption of cell membrane integrity 
and leakage of intracellular constituents 
function as danger associated mol
responses (Bianchi 2007). In reality, a continuum exists between apoptosis and necro
and an ample diversity of mechanisms mediating cell death 
Valdez et al. 2011). 
 
The first immunological response to HI brain injury is acti
like microglia (Denker, Ji et al. 2007
Microglial cells can directly cause increased secondary injury due to TNF
neurotoxicity (Kaushal and Schlichter 2008
implicated. Microglia act as antigen pre
to the microenvironment 
ucting agents. Some of
 are named alarmins or damage associated molecular patterns (DAMP
ing the blood brain barrier for 
comprehensible that addition of an 
 
 determining neurological outcome 
; Liu and McCullough 2013
rain barrier excludes circulating immune cells and 
ivileged site (Bucky Jones, Lucin et al. 
protect itself 
have the capacity to 
).  
 

between energy consumption and production 
vere enough, 
is (Thornton, Rousset et al. 
 cell stress, and extrinsically due to extracellular 
ar environment 
(Northington, ChavezValdez et al. 2011
ecular patterns (DAMP)/Alarmins to trigger immune 
(Northington, Chavez

vation of resident brain cells 
) and astrocytes (Pekny and Nilsson 2005

). Noxious nitric oxide release has also been 
senting cells (APCs) through upregulation of 
 
 the released 
s). 
). Under 
(Thornton, 
) that 
sis 

). 
α induced 
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HA molecules, costimulation and cytokine production (ai and Todd 2006), thus 
providing all three signals necessary for Tlymphocyte activation (apsenberg 200). 
However, microglia are not only harmful since they are involved in clearance of 
cellular debris and produce beneficial growth factors important for regeneration and 
recovery after a brain lesion. 
Astrocytes are crucial for regulation of extracellular glutamate, an excitatory amino 
acid neurotransmitter that can cause excitotoxic lesions if abundant (AlvareDia, 
Hilario et al. 2007). Moreover, astrocytes have a major impact on blood brain barrier 
function and play a key role in regulating both blood flow and blood brain barrier 
permeability (Dare, Schulte et al. 2007). Astrocytes display some features coherent 
with antigen presenting capacity, however, if it actually occurs is controversial. 
 
To elicit a specific Tlymphocyte mediated immune response, an antigen presenting cell (APC) (green) 
present the antigen (plum) mounted on the major histocompatibility complex (MHC) to the Tlymphocyte (blue). The 
MHCpeptide complex is recognied by the Tcell receptor providing signal one in Tlymphocyte activation. Co
stimulation necessary for activation is provided through signal two; CD80 or CD86 expressed on antigen presenting 
cells and recognied by Tlymphocytic CD28. Signal three consists of cytokines (yellow) released by the antigen 
presenting cell to direct the type of Tlymphocyte response.
 
The hypoxic ischemia induced breakdown of blood brain barrier function opens the 
brain for infiltration of systemic immune cells (Bona, Andersson et al. 1999; Hedtjärn, 
Mallard et al. 2004).  

Macrophages are one of the first cell types to infiltrate the brain after hypoxic ischemia, 
responding to DAMPs and cytokines (Denker, Ji et al. 2007). Phenotypically 
infiltrating macrophages and brain resident microglia are virtually indistinguishable, 
and thus the distinction between them functionally is an academic question. However, 
their anatomical location and temporal distribution in relation to the infarction matters, 
since cells separated on these criteria express different markers and have thus slightly 
alternative functions (Perego, Fumagalli et al. 2011). Microglia/macrophage activation 
is probably harmful since blockade of inflammatory mediators produced by these cells 
 10 
is protective (Perego, Fumagalli et al. 2011). However, since it is impossible to 
completely deplete or block microglia/macrophage cells in brain there is no 
indisputable evidence. wo alternative ways of activation has been described, pro
inflammatory M1 and the regulatory antiinflammatory M2 response (Lawrence and 
Natoli 2011). M2 induced macrophages seem to protect against hypoxic ischemia 
 but not (Desestret, Riou et al. 2013) possibly because local environment 
 is more important in microglia/macrophage function than intrinsic activation in 
this study. Nonetheless, understanding of microglial function and regulation continues 
to be an area of great interest for the development of neuroprotective strategies. 
Natural killer cells (Ncells) are involved in, as the name implies, cytotoxic killing 
and seem to play a role in neonatal brain injury (Bona, Andersson et al. 1999; Fathali, 
Ostrowski et al. 2013). However, their contribution to brain injury and mechanistic 
function during brain injury is not well described. 
Neutrophils infiltrate the adult brain after brain injury, but their influence in the 
neonatal brain appears to be minor (Liu and McCullough 2013). 

lymphocyte activation after neonatal H brain injury has been demonstrated 
indirectly (Bona, Andersson et al. 1999; Hedtjärn, Mallard et al. 2004). Classical 
activation of lymphocytes requires antigen presentation by antigen presenting cells 
(APCs) to naive lymphocytes. Costimulatory signals are necessary for the 
lymphocyte activation, and soluble and membrane bound factors directs the type of 
response launched (apsenberg 2003). ith regards to brain injury,  and B
lymphocytes depleted adult animals were protected as early as 22h after middle 
cerebral artery occlusion (MCAO) suggesting other acute functions than initiation of 
specific antigen recognition with subsequent clonal expansion and proliferation. 
Blockade of lymphocyte trafficking also protected the adult brain (Liesz, Zhou et al. 
2011). Furthermore, corresponding to the situation in microglia/macrophages there is 
also a regulatory antiinflammatory population that have been reported to convey 
neuroprotection (Liesz, SuriPayer et al. 2009). Although these data suggest that 
lymphocytes are detrimental after ischemic brain injury, the functional status in the 
neonatal setting and whether they are able to respond to brain antigens is unknown. 
Blymphocytes are best known for their ability to produce antibodies, but they are also 
able to present antigens to cells (Ciechomska, Lennard et al. 2011). he existence of 
regulatory Blymphocytes (B10) has also recently been proposed (Mauri and Bosma 
2012). However, the regulatory function appears to be a transient state involved in 
normal activation and not necessarily a discrete function (Maseda, Smith et al. 2012), 
which seems reasonable since it would be beneficial to limit unspecific activation once 
a specific response to the presumed threat is present. Nonetheless, Bcell deficient mice 
develops larger infarction after MCAO in the adults (Offner and Hurn 2012). Offner 
 suggest adoptive transfer of regulatory Blymphocytes as a therapeutic approach for 
neuroprotection. However, this (or any transfer of immune populations with capability 
of immunological memory) could potentially be hazardous with risk of immunological 
reactivation later in life and induction of autoimmunity (Hagberg, Gressens et al. 2012). 
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5.1.2 Preconditioning effects of systemic inflammation 
Perinatal infections induce adverse cognitive development (van Vliet, de Kieviet et al. 
2013), and cytokines (Aden, Favrais et al. 2010) or LPS (Hagberg, Peebles et al. 2002) 
treatments are used in experimental models to mimic and understand how this effect is 
mediated. hile short term detrimental effects after brain injury are seen after L1, 
TNFα and LPS treatment, protective properties are observed after somewhat longer 
time (Dammann and Leviton 1997; Mallard and Hagberg 2007; Kendall, Hristova et al. 
2011). LPS, L1 and TNFα share some of the intracellular signaling cascades 
explaining the similarity in effect (Ferlito, Romanenko et al. 2001). One way to explain 
the dual effect is the danger hypothesis proposed by Matzinger (Pradeu and Cooper 
2012), stating that immune activation is directed towards harmful dangerous stimuli. 
Moderate doses of L1, TNFα or LPS do not represent any genuine danger, and 
therefore the pro inflammatory deleterious response is abolished. This hypothesis could 
also be applied to the similarities between infectious inflammation and aseptic 
inflammation during brain injury. Since both presents as actual threats to cell survival, 
an immune response is launched to attempt to terminate the harm by cytotoxic killing 
of injured cells and clearing of extracellular debris. 
5.1.  
TNF is produced by all major cell types in the brain, microglia, astrocytes and 
neurons, and is a key cytokine in immune responses. The effect of TNF signaling 
varies between brain regions, and has principal functions in brain physiology and 
homeostasis including effects on excitatory amino acids, long term potentiation and 
plasticity, implicating impact on memory formation (O'Connor 2013). Thus, during 
long term blockade of TNF, like in the treatment of juvenile idiopathic arthritis 
(Gerloni, Pontikaki et al. 2008), adverse effects on cerebral function occur. There are 
two receptors for TNF, receptor one (TNFR1) and two (TNFR2) with diverse (Sriram 
and O’Callaghan 2007) but somewhat overlapping effects. The receptors are involved 
in regulation of both apoptosis and proliferation via the TNF receptor associated death 
domain (TRADD) and pathways leading to subsequent activation of the transcript 
factors activator protein 1 (AP1) and nuclear factor kappa beta (NFκB) (O'Connor 
2013). However tentative, a connection with TNF to adenosine receptor signaling has 
also been implicated (Trincavelli, Tonazzini et al. 2008). 
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5.2 ADENOSINE 
 
There are four subtypes of adenosine receptors A1, A2A, A2B and A3. All are coupled to Gproteins; A1 and 
A3 are coupled to Gi, inhibiting the formation of cAMP, whereas A2A and A2B stimulate cAMP through Gs coupling. 
Adenosine signaling is situated at the crossroads of many fundamental functions 
involved in the homeostasis of physiological functions (Fredholm, AP et al. 2001). It is 
linked to the basic metabolism of every cell in the body since the majority of the 
available adenosine comes from degradation of adenosine triphosphate (ATP) a 
molecular transporter of chemical energy within the cell (Shampo, Kyle et al. 2011). It 
assists in the regulation of cardiac and vascular function, and adenosine administration 
is used clinically to stop and reboot the heart to treat heart arrhythmias. It is active in 
the brain where it regulates cell work, thus protecting the brain during hypoxic 
ischemia when energy is absent. Furthermore caffeine, the best known and most 
consumed adenosine modulating drug (limiting adenosine signaling) is often used for 
its stimulatory effect on brain in a variety of refreshing beverages. Furthermore, 
adenosine is involved in control of the breathing rhythm (Darnall and Bruce 1987) and 
body temperature (Fredholm, Johansson et al. 2011). Of particular interest in this thesis, 
adenosine also has major effects on immune regulation (Fredholm 2007; Linden and 
Cekic 2012). The above mentioned effects are only the ones of known importance in 
hypoxic ischemic brain injury. In addition, adenosine has known effects on skeletal 
muscles, kidney and fat metabolism (Fredholm, Johansson et al. 2011), and adenosine 
receptors are present in high levels in the eye, adrenal gland, ceacum, colon and in the 
bladder. 
Still, it is possible to deplete mice of each of the four available adenosine receptors and 
the animals appear with essentially normal phenotype. This highlights that adenosine 
has a modulatory rather than controlling role during normal physiology. However 
during extreme physiology and pathology the impact is substantial (Fredholm 2007). 
During hypoxia adenosine signaling can exert both protective and detrimental effects. 
This functional diversity is achieved through differential intra cellular signaling 
pathways in combination with dynamic regulation of receptor distribution and density. 
There are four subtypes of adenosine receptors A1, A2A, A2B and A3, where A1 and A3 
are coupled to Gi that inhibit the formation of cAMP while A2A and A2B receptors are 
coupled to Gs, and thus stimulate cAMP formation (Figure 3). Moreover, the receptor 
subtypes induces various other intracellular signaling pathways, thus further 
differentiating the signal (Fredholm, AP et al. 2001). 
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The affinities for adenosine vary between the receptor subtypes, where A1 has the 
highest and A2A and A3 lower binding in decreasing order. A2B has the lowest binding 
affinity and hence is only activated during extreme physiology or pathology like 
hypoxic ischemia (Fredholm, AP et al. 2011). 
During brain hypoxic ischemia, adenosine levels available for signaling are mainly 
from extracellular breakdown of ATP. Disruption of the cell membrane during hypoxic 
ischemic injury leads to leakage of abundant intracellular ATP, readily cleaved by the 
ectonucleotidases CD39 and CD73 to form adenosine. During pathology, the 
extracellular concentrations can increase four to five orders of magnitude. Adenosine is 
degraded by adenosine deaminase (ADA), which thus acts to limit exaggerated 
adenosine levels. 
5.2.1 Adenosine as an immune modulator  
Adenosine has a profound impact on immune function and deletion of the enzyme 
responsible for degradation of adenosine, adenosine deaminase, results in severe 
combined immunodeficiency (SCID) and altered immune cell function (Cassani, 
Mirolo et al. 2008). Extensive research has been attributed adenosinergic immuno
modulation and most immune cell populations express some or all of the four 
adenosine receptor subtypes, depending on functional status and activity (Fredholm 
2007; Hoskin, Mader et al. 2008; Kumar and Sharma 2009). In the context of tumor 
immunology a substantial accumulation of knowledge has been made regarding 
adenosine mediated immune regulation both in immune compartments and among 
tumor infiltrating cells (Kumar 2013). However, after brain hypoxic ischemia with a 
dissimilar microenvironment, much less is known and age differences further restrain 
unambiguous extrapolation from the present data obtained from tumor and   
experiments in adults. 
5.3 CAFFEINE 
Caffeine is currently used as a treatment for apnea of prematurity and in a randomized 
clinical trial been found to decrease the incidence of cerebral palsy and cognitive delay 
at eighteen months (Schmidt, Roberts et al. 2007). Furthermore, MRI findings report 
improved white matter development after caffeine treatment in preterm children 
(Doyle, Cheong et al. 2010). Nonetheless, the use of caffeine has been hampered due to 
safety concerns regarding; neurotoxicity, impaired development, and detrimental 
effects on long term behavior. Caffeine as a treatment in neonates was first proposed 
1973 by Kuzemko as a treatment for apneasalthough the effect on respiration was 
described as early as 1927 by ogl (ucey 197). The Cap study 2002007 potentially 
expanded the indications for caffeine use to include neuroprotection (Schmidt, Roberts 
et al. 2007). 
Caffeine is a competitive inhibitor of all adenosine receptors except the adenosine A3 
receptor that has low affinity for caffeine (Fredholm, Battig et al. 1999). Since A2B 
receptors are only activated when adenosine levels are high (see above) the effect of 
caffeine in physiological conditions is mainly due to A1 and A2A effects, although A2B 
probably plays a role during hypoxic ischemia. Furthermore, caffeine has the potential 
to inhibit the enzyme phosphodiesterase (PDE). Many of the (adverse) effects from 
caffeine have been attributed to PDE inhibition. However, phosphodiesterase inhibition 
requires 20 times higher concentrations than its effects on adenosine receptors 
(Fredholm, Battig et al. 1999), well above the concentrations reached during treatment. 
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The inhibition of PDE after therapeutic doses in neonates is probably minor (Aden 
2011). Caffeine in clinically relevant concentrations could also potentially increase 
adenosine deaminase activity after brain hypoxic ischemia when adenosine levels are 
high (Leon, Michienzi et al. 2007; Xu and Venton 2010), thus further limiting 
excessive adenosine signaling. 
5.3.1 Adverse effects of caffeine 
Impaired growth in neonates has been reported in studies of suboptimal design after 
maternal caffeine intake, reviewed by (Aden 2011), however the only randomized 
doubleblind controlled trial found no effects on birth weight (Bech, bel et al. 2007). 
It is problematic to assess effects of caffeine in human studies, since intake is 
exceedingly difficult to estimate and the effect confounded by a number of factors  
smoking, alcohol, race and education (Valero De Bernabe, Soriano et al. 2004). 
Furthermore, it has been suggested that cytochrome P450 1A2 function, the enzyme 
responsible for caffeine degradation and clearance, is correlated to growth retardation 
rather than caffeine itself, that merely acts as a pseudo marker for cytochrome p450 
1A2 function (Grosso, Triche et al. 2006). 
Behavioral changes have been reported in rodents after prenatal caffeine exposure, 
however, prospective human studies concluded that the long term consequences at the 
age of seven was null (Barr and Streissguth 1991; American Psychological Association. 
Division of General Psychology. 1997). Postnatal high dose caffeine (20 mg/kg/day 
compared to the normally used dose of 5 mg/kg/day) given to preterm infants as apnea 
prevention found no adverse outcomes (Steer, Flenady et al. 2003; Steer, Flenady et al. 
2004; Gray, Flenady et al. 2011) at one and two years of age. 
In conclusion, there is no evidence in unbiased high quality studies of persistent 
detrimental effects in neonates when clinically relevant therapeutic concentrations of 
caffeine are used. Due to the intricate nature of caffeine intake and biological function, 
only randomized, controlled, prospective studies are appropriate to consider when 
attempting assessing adverse outcome without significant bias. 
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6 AIMS 
In this work we aimed to study the mechanisms of hypoxic ischemic brain injury in the 
neonatal period with focus on inflammation and adenosine receptor signaling as targets 
for neuroprotective intervention. 
1. To study if blockade of T offers protection against brain injury in two 
different models of immature brain injury 
2. To investigate immune cell activation locally in the brain and systemically in 
spleen after brain hypoxic ischemia.  
 To develop a flow cytometry based method of investigation 
 To describe adaptive immune activation. 
3. To assess the effect of adenosine A1 receptor deletion on outcome after hypoxic 
ischemic brain injury. 
 To adopt data driven analysis for brain infiltrating immune cells and 
statistically discriminate genotype and injury size effects. 
 To investigate if brain inflammation, could be a significant factor 
affecting outcome after brain hypoxic ischemia in adenosine A1 receptor 
deficient neonatal mice. 
4. To evaluate the effect of adenosine A2A receptor deletion on brain injury and 
post ischemic inflammation 
5. To test if a single dose of 5 mg/kg caffeine after brain hypoxic ischemia is 
neuroprotective and the effect on cellular immune activations. 
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7 MATERIAL AND METHODS 
7.1 HYPOXIC ISCHEMIA 
In mice pups unilateral elecrocoagulation of the carotid artery was performed under 
Isoflourane sedation and local Bupivacaine anesthetic. Extensive care was taken to 
avoid stress to the mothers that when herself was calm, seemed able to calm the pups 
after the procedure. 
Each animal operation typically takes less than 3 minutes per animal. Since longer 
isoflourane exposure could interfere with outcome (McAuliffe, Loepke et al. 2009), 
only animals operated within one hour were used in the same experimental run. After 
one hour of recovery and feeding with the dam the pups were put in hypoxia at 10% 
oxygen for one hour, to induce unilateral focal brain lesions similar to those seen in 
hypoxic ischemic encephalopathy of newborn children (Vannucci 2004). We have used 
ten day old mice that are similar to newborns in respect of white and grey matter 
development (Clancy, Finlay et al. 2007). There is however important differences 
between mice and men. Firstly, mice lack sulci, an important feature of the human 
brain cortex. They also have a different behavioral repertoire; they are nocturnal, small 
in size and depend on other primary senses than humans. Smell is the primary sense of 
mice and thus the olfactory bulb of mice is substantially larger and the major input 
wiring of neurons is thus somewhat different than in man. Having said that, the 
similarities are extensive and 99% of the mouse genome has direct counterparts in man 
(Gunter and Dhand 2002), which is why the mouse is considered an appropriate model 
to study brain injury. Even if an observation in the mouse not necessarily translates 
directly to the same function in humans, there is a great likelihood that similar 
molecular mechanisms can be found and studied. Mice studies also offer a great 
opportunity, as it is possible to eliminate genes of interest to test their function in 
different experimental models. There are  models available but when studying 
immune cell responses after brain injury, an intact immune system, a blood brain 
barrier and vascular circulation is required. 
7.2 EXCITOTOXIC BRAIN INJURY 
Ibotenate an NMDA and metabotrobic glutamate receptor agonist was injected 
intracranially to induce excitotoxic brain lesions, where the major deleterious effect 
was mediated through NMDA activation (Marret, Mukendi et al. 1995). We used five 
day old mice, an age comparable to week 2430 in humans a period during brain 
development when immature oligodendrocytes are exceedingly vulnerable to injury, 
causing lesions similar to periventricular leukomalacia of preterm babies (Hagberg, 
Peebles et al. 2002). 
7.3 BEHAVIORAL EVALUATION 
Functional deficits is the impairment that is perceived after brain injury, not infarct size 
or any other change seen in the brain, thus we investigated the behavioral effect of 
hypoxic ischemic brain injury. We used a small array of tests, always according to a 
detailed preset protocol and in the same order with the operator blinded to the variable 
investigated. Since, mice are easily disturbed and react to the operators behavior, smell 
and handling the experiment protocol included all handling of litters and mice, even 
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before the actual experiment started, and a recently showered, unparfumed and peaceful 
operator, to ensure a calm and explorative state of the mice. First we used the open field 
test where the movement and behavioral patterns is recorded with sensors and/or a 
camera in an empty acrylic glass box. A quiet, undisturbed surrounding is crucial since 
every sound directly will influence the behavioral reading. To minimize the bias from 
unexpected disturbances, cases and controls were run simultaneously, thus they should 
be comparable although noise is added to the behavioral signal. Directly after open 
field test we performed the beam walking test, where the mice balance a one centimeter 
wide beam three times, while slips with the hind limbs are counted. This test was the 
most sensitive detecting brain injury in our hands and simultaneously the most sensitive 
for disturbances. When stressed mice run over the beam in an attempt to escape, they 
perform fairly well even with brain injury. However, when calm they start to 
investigate the beam that triggers an explorative behavior rendering inattention of 
motor performance and unveiling functional deficits. A test less vulnerable to stress, is 
the Rotarod test, where the mice attempts to stick to an accelerating rod and time on or 
maximum speed is recorded. In this purely motor function test a certain activity and 
excitement in the mouse boost performance. To avoid misinterpretation, fear or pain is 
not excitement and the mice should appear enriched when performing the test. 
7.4 IMMUNOHISTOCHEMISTRY 
The brains collected for immunohistochemistry were first percoronary perfused with 
PBS to avoid autofluorescence from vascular erythrocytes. The brains were collected, 
snap frozen on dry ice and then cryosectioned in 1014 m slices. The tissue was 
fixated in 4% Paraformaldehyde for 10 min and blocked with serum from the same host 
as the secondary antibody or horse serum 350% volume concentration. We have found 
that higher serum concentrations up to 50% reduced background more efficiently, 
however most antibodies used in this work had a sufficient noise to signal ratio why 
there was no need for such high serum concentrations. Primary antibody was used after 
titration of optimal concentration and with irrelevant primary antibody as negative 
control. Secondary antibodies were either species specific, isotype specific or mouse on 
mouse kit was used according to manufacturer's specifications. All secondary 
antibodies were tested without primary antibody to assess unspecific binding. Detergent 
(tritonx100, saponin or Tween20) were used in the blocking solution for intracellular 
staining (Jamur and Oliver 2010) and also for the last wash to break hydrophobic 
nonselective binding of antibodies. For light microscopy, horseradish peroxidase 
staining was typically performed and preceded by blocking of endogenous peroxidase 
activity with 0.3% hydrogen peroxide. Please see manuscripts for detailed protocols 
used in each study. To evaluate density of the staining and to be able to compare 
antigen expression between treatments or genotypes, the enzymatic step was performed 
simultaneously for all samples, ensuring comparability and integrated density was 
measured (pixels stained times intensity of staining in each pixel). 
7.5 ELISA 
Cells lysis buffer was used to disrupt cell membranes in the presence of phenylmethyl 
sulfonyl fluoride (PMSF) to avoid protein degradation. The lysate was centrifuged and 
supernatant collected for cytokine analysis using commercial ELISA kits in accordance 
to the manufacturer´s specifications.  
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7.6 WESTERN BLOT 
Cells were lysed and proteins were separated through consecutive centrifugation steps. 
Protein concentrations were measured and a fixed amount of protein was denaturated 
with Laemmli sample loading buffer at 95°C. To further disrupt secondary, tertiary and 
quaternary structures natriumlaurilsulfate (SDS) was used and proteines separated 
using polyacrylamid gel electrophoresis and electrotransferred to a nitrocellulose 
membrane. Reversible Ponceau S staining was used to confirm equal loading and 
protein transfer. Proteins of interest were immunostained and detected by the enhanced 
chemiluminescence system (ECL, Amersham) and densiometrically analyzed with the 
image analysis environment TINA. 
7.7 PROLIFERATION ASSAY 
Thymidine incorporation based proliferation assays with brain homogenate as stimulus 
were set up to investigate the proliferation of spleenocytes from animals subjected to 
hypoxic ischemic brain injury and sham operated controls. The time to peak 
proliferation was estimated and used as optimal evaluation time point for each antigen 
prior final experiments, for details see paper II. 
7.8 REAL TIME QUANTITATIVE POLYMERASE CHAIN REACTION 
Messenger ribonucleic acid (mRNA) was extracted from brain tissue adjacent to the 
injury site by two consecutive total RNA isolation procedures including a DNAse I 
digestion step to degrade contaminating genomic DNA. Reverse transcription was 
performed using Iscript kit from Biorad. Sample not exposed to reverse transcription 
was used as negative controls to exclude remaining contamination of genomic DNA. 
All experiments were run in duplicates. Primers were designed using Oligo .0 and M
fold software. For primer sequences see manuscript I. 
7.9 FLOW CYTOMETRY 
The brains were perfused percoronary with 10 ml PBS to flush out circulating blood 
cells, since we set out to investigate brain infiltrating immune cells and not the vascular 
compartment. The cerebellum and the frontal part of the brains were removed and the 
infarcted and contralateral hemispheres were collected so as to include the part of the 
brain where the infarction is, and contralateral side. Tissues were then put in ice cold 
medium and kept cool to avoid in vitro activation and cell death. The brains were 
homogenized using a loose fit glass homogenizer and filtered through a 100 µm filter to 
remove supportive tissue and large cells that could clog the cytometer. Erythrocytes 
were lysed with hypotonic ACK buffer for five minutes, which preferentially removes 
cells without nucleus that are more sensitive to the hypotonic condition. No additional 
purification steps were performed to avoid in vitro activation and manipulation (Fung, 
Esposito et al. 2010). Other groups sometimes use Percoll purification (Gelderblom, 
Leypoldt et al. 2009). We have found that every extra cleaning step preferentially 
drains the activated compartment of tissue infiltrating cells (unpublished data), that 
induces bias. Thereafter cells were stained with fluorescence conjugated antibodies, 
washed and analyzed in the flow cytometer. 
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7.10 DATA DRIVEN ANALYSIS OF FLOW CYTOMETRY DATA 
We deployed a R based approach of probabilistic data driven analysis using the 
flowCore (Hahne, LeMeur et al. 2009) and flowViz (Sarkar, Le Meur et al. 2008) 
packages that are reported to perform well (Aghaeepour, Finak et al. 2013). We adapted 
the methodology to brain infiltrating populations since the presentation of immune cells 
in solid tissue differs substantially from the roundish form in liquid where guidelines 
for gating exist (Calvelli, Denny et al. 1993). We chose to use a probabilistic function 
to interpret the populations in brain since the populations have not been previously 
investigated and normal distribution could not be assumed. Since the brain in an 
unchallenged state is fairly immuno privileged (Bucky Jones, Lucin et al. 2007) and 
often no clear positive immune cell population could be found, we localized the 
negative population and cells with higher expression of the marker investigated were 
assumed to be positive. All gates were manually confirmed for appropriateness, but 
after fine tuning of the algorithm no further adjustments were needed and the same 
settings were used in all experiments investigating the same markers in the same 
locations,  brain and spleen respectively. 
7.11 STATISTICAL ANALYSIS 
For comparison of two experimental groups ttest was used when normal distribution 
could be assumed, otherwise the nonparametric MannWhitney test of pairwise 
comparison was used. Chisquare test was used to detect the frequency distribution of 
mortality. ANVA multiple comparisons and Neumaneuls, Tukey or Dunnett post 
hoc test when appropriate to analyze multiple factors influencing the outcome of a 
variable. General linear model (GLM) regression was used to evaluate correlations 
between variables. Furthermore, we used principal component analysis (PCA) to 
reduce the dimensionality of multiplex flow cytometry data, allowing us to analyze and 
separate genotype effects from the effects due to brain injury size in our model. T2 
Hotelling and squared prediction error was used to validate the integrity of the data sets. 
The Nonlinear Iterative Partial Least Squares (NIPALS) algorithm was selected since it 
allows for inclusion of categorical values (like genotype) and thus allowed us to 
evaluate the covariation of genotype and the immune populations investigated. To 
group immune populations that had a similar representation on the components 
identified in the PCA analysis, and thus may have similar or connected functions we 
used expectation maximization clustering that uses an probabilistic approach to assign 
cluster belonging. To identify the appropriate number of clusters to analyze we used v
fold cross validation to avoid the potential bias that occurs when cluster number is 
assigned subjectively. Thus we minimized the need for extensive experiments and 
maximized the amount biologically relevant information extracted from the dataset 
without introducing major bias from brute force (analyzing all possible combinations of 
variables) large scale data analysis. 
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8 RESULTS AND DISCUSSION 
8.1 TNF IN NEONATAL BRAIN INJURY (PAPER I) 
We found that systemic IL1 induced inflammation increased the susceptibility to 
brain injury in the preterm excitotoxic model. This effect is abolished through 
pharmacological blockade of TNF (Etanercept) given after the hypoxic ischemic 
insult or deletion of the TNF gene, producing a lesion size equivalent to those in 
animals not subjected to the systemic IL1. IL1 treatment increased TNF 
production that thus seemed to mediate the detrimental effect. However, we performed 
a pilot study to investigate IL1 induced systemic inflammation in a full term model of 
hypoxic ischemia and preliminary data suggests a preconditioning protective effect of 
five day IL1 treatment (unpublished data). Thus age and mode of injury appear 
crucial for outcome, and the premature period might be associated with increased 
susceptibility to excitotoxic injury during inflammation. 
We then continued to investigate TNF blockade in a more naturalistic inflammatory 
insult by injecting systemic lipopolysaccharide (LPS), a lipoglycan expressed on gram 
negative bacteria, 24 hours prior the hypoxic ischemic insult in the full term model. We 
found no significant differences between Etanercept pre or posttreated animals 
compared to PBS treated controls (Figure 4). Since TNF blockade seems to protect 
only against inflammatory sensitization (Aden, Favrais et al. 2010) and it is now known 
that LPS induced sensitivity to hypoxic ischemia is greatest twelve hours after systemic 
administration (Kendall, Hristova et al. 2011) and even induce preconditioning 
protective effect 24 hours after administration (Mallard and Hagberg 2007), our 
findings are in retrospect, not surprising. Nonetheless, it stresses the importance of 
timing in a possible TNF targeted neuroprotective treatment. In combination with 
beneficial TNF effects (see background) as growth factor and regulator of neural 
function there are major hurdles to overcome to allow clinical use, and still only a 
fraction of the children (those with systemic inflammation) would potentially benefit 
from the intervention, why TNF blockade is not a primary candidate for neonatal 
neuroprotection today. 
 
There were no significant differences due to TNF blockade with the decoy receptor Etanercept given before 
or after hypoxic ischemia, neither in total tissue loss seen by loss of MAP2 staining nor in myelin content visualized 
by myelin basic protein (MBP). 
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 RAI IEIIRAI A EI AIAI 
(PAPER II) 
The presence of adaptive immune cells in the brain after neonatal brain injury has been 
described (Bona, Andersson et al. 1999; Hedtjärn, Mallard et al. 2004). However, the 
temporal correlation between key immune populations and their interplay was 
unknown. We set out to investigate the adaptive component of immune activation and 
the relationship with innate immune activation and antigen presentation locally in the 
brain and systemically in the spleen. Since the number of adaptive immune cells was 
expected to be low compared to other cell types in the brain and we sought to 
investigate functional markers involved in activation and initiation of an adaptive 
immune response, we developed a multiplex flow cytometry based methodology to 
investigate both brain parenchyma infiltrating and systemic immune activation in the 
spleen after brain hypoxic ischemia. 
 
Cellular immune profile in brain and spleen after neonatal hypoxic ischemia. 24 hours and two weeks after 
injury CD11b+CD86+ cells increase in a biphasic pattern (black line) coherent with initial activation of brain resident 
microglia followed by infiltration of systemic macrophages. Very early activation antigen CD69+ Tlymphocytes 
were found in the spleen (red dotted line) on week after the lesion, preceding CD8+ cytotoxic Tlymphocyte 
activation and brain intrusion (reen short dashed line). Tlymphocyte activation continued at least three months, 
when the highest number activated CD8+ cytotoxic and CD4+ helper (blue long dashed line) were found, returning to 
pre insult levels seven months after brain hypoxic ischemia. 
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Innate immune activation was observed 24 hours after brain hypoxic ischemia and a 
second peak one week after the lesion. The first peak has been reported to consist of 
brain resident cells while the second peak represents infiltrating systemic immune cells 
(Denker, Ji et al. 2007). Furthermore, we could visualize an increase in the fraction 
innate cells expressing the costimulatory molecule CD86 in the spleen one week after 
the lesion, suggesting systemic antigen presentation. Interestingly, inhibition of this 
activation through spleenectomy has now been reported to ameliorate the infarction 
volume after neonatal hypoxic ischemia (Fathali, Ostrowski et al. 2013). Subsequent 
activation of antigen presenting cells, preferentially activated CD8+ cytotoxic cells, was 
found in the brain and spleen at the same time, one week after the lesion. At this time a 
large proportion were naive Tlymphocytes expressing CD45rb, indicating that they 
had not yet encountered their cognate antigen. Intriguingly I4 and I13 production 
with suggested antiinflammatory properties have been described after hypoxic 
ischemia (Shrivastava, lovera et al. 2013). However I4 and I13 are able, at least 
under some conditions, to activate and promote proliferation and memory phenotype in 
CD8+ cytotoxic Tlymphocytes (orris, Heidorn et al. 200), hence their function seem 
more coherent with a transition towards adaptive immune activation. The highest T
lymphocyte activation was observed in the brain three months after the lesion, then 
consisting of CD4+ Thelper and CD8+ cytotoxic cells, both of mainly CD45rb effector 
phenotype. This phenotype was confirmed by the fact that spleenocytes from animals 
subjected to brain hypoxic ischemia lost their tolerance toward central nervous system 
antigens and proliferated when stimulated with brain or spinal cord homogenate. The 
ability of Tlymphocytes to respond to brain antigens persisted unaltered for at least 
five months once developed. Thus Tlymphocyte activation strongly suggests a long 
term effect of Tlymphocytes in the pathology after brain injury and possibly long term 
development of autoimmunity upon reactivation due to cellular damage in brain 
initiated by, for example infection or trauma, that could result in persistent immune 
mediated neuropsychiatric disability (Hagberg, Gressens et al. 2012). Interestingly, a 
recent publication suggested that mesenchymal stem cells transplantation protected the 
brain after global hypoxic ischemia partly due to diminished Tlymphocyte infiltration 
and induction of tolerance (Jellema, Wolfs et al. 2013). 
8.3 ADENOSINE A1 DEFICIENCY (PAPER III) 
Adenosine A1 receptor deficient mice were more susceptible to brain hypoxic ischemia 
than wild type mice. Increased injury in the A1 deficient mice manifested as functional 
deficits in behavioral tests and as increased infarction size in histological sections. 
One major hurdle to overcome when using multiplex flow cytometry is to reproducibly 
produce gate settings to select the immune cell populations for analysis. This is 
particularly difficult in brain parenchyma where immune populations acquire a more 
ramified structure and somewhat altered cellular distribution of the antigens 
investigated (as seen in immunohistological sections). We therefore developed a 
probabilistic approach to gate assignment that excluded the manual bias and allowed 
exactly the same result to be produced when reanalyzed, and consistent addition of new 
data when included. Furthermore, as this approach used the density of the populations 
and we used a simple binary strategy determining positive or negative cells, thus 
fluctuations in the laser intensity due to intrinsic variability in the flow cytometer could 
be accounted for. In order to validate the selection of populations to some degree, we 
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investigated the distributions and found that the data driven gating strategy generally 
produced populations more coherent with normal distribution. Since this finding also 
could be explained by the algorithm producing nonsense populations that inherently 
followed normal distribution we manually confirmed all gates in all samples and 
experiments and found the gates to be assigned satisfactory. 
After analyzing the data one population at a time using ANOVA to investigate sham or 
hypoxic ischemic treatment, and wild type and adenosine A1 deficient genotype the 
overall picture was still elusive. It was difficult to assess which populations were 
altered in a similar way and thus might have similar or connected function. We 
therefore deployed principal component analysis (PCA) using the nonlinear iterative 
partial least squares (NIPALS) algorithm that allows inclusion of dichotomous data 
such as genotype in our case. We were not able to experimentally assess damage size in 
the same animals that were used for flow cytometric analysis due to technical 
limitations. However, we realized that we could use principal component analysis to 
discriminate between genotype and injury size since the injury induced variance was 
similar in both genotypes. Principal component analysis construct components 
consisting of the combined covariation in the variables investigated thus reducing the 
dimensionality, where every additional component is by definition uncorrelated to the 
previous one. We extracted two components including only the significantly affected 
immune populations which could describe as much as 90% of the variance in our 
model. When plotting genotype against sham operated or hypoxic ischemic brain injury 
we could identify immune populations affected by the lesion size only, by genotype or 
a combination of the two. Furthermore, when each animal was plotted against the 
components they formed individual clusters. Thus we hypothesized that it should be 
possible to genotype the animals using the immune profile in sham and after brain 
injury. In fact we were able to correctly classify both treatment received and genotype 
in 90% of the cases using expectation maximization clustering and vfold cross 
validation to determine correct number of clusters. Interestingly, some alterations in the 
immune responses were better explained by genotype than lesion size where the most 
profound were diminished activation of cytotoxic Tlymphocytes and regulatory IL10 
producing Blymphocytes. The absence of a cytotoxic response in the A1 deficient mice 
could reflect a shift in cell death mechanism from apoptosis to necrosis since adenosine 
A1 receptors are known to protect against excitotoxicity during the insult (Fredholm 
2007) – manifested as increased infarction size after hypoxic ischemia. The altered 
response in Blymphocytes that produced IL10 implies impaired Bregulatory cell 
function (Mauri and Bosma 2012). Furthermore, we found decreased overall levels of 
IL10 that at least to some extent could explain the observed phenotype and suggests a 
novel mechanism of adenosine A1 receptor mediated control of Bregulatory cells 
(B10) in tissue. 
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Most brain B220+ Blymphocytes (red) produced I10 (green), the hallmark cytokine of Bregulatory cells 
(B10) two weeks after hypoxic ischemia. ot all I10 producing were Blymphocytes. 
8.4 ADENOSINE A2A DEFICIENCY (PAPER IV) 
Both protective and detrimental effects of adenosine A2A receptor blockade have been 
reported after hypoxic ischemic brain injury. In this paper we present a novel 
hypothesis that short term (hours to days) blockade is beneficial through non
immunological mechanisms and long term (two weeks) detrimental, likely through 
immunomodulatory effects as suggested by our data (see below). The most prominent 
effects in the adenosine A2A receptor knockouts after brain hypoxic ischemia were in 
regulatory antiinflammatory populations like myeloid derived suppressor cells that 
were significantly fewer in the knockout. Adenosine is known to mediate a substantial 
part of the Tregulatory antiinflammatory effect (Sitkovsky, ukashev et al. 200), and 
accordingly there was a substantial compensatory increase in CD4+FoxP3+ T
regulatory cells after brain injury in A2A knockout mice. Deficiency in immune 
regulatory functions in adenosine A2A knockout mice was paralleled by increased 
activation in cytotoxic natural killer cells and CD8+ Tlymphocytes. Moreover, 
CD86+CD11b+ microglia/macrophages were significantly increased, coherent with the 
larger injury seen in the knockouts compared to wild type. Since short term adenosine 
A2A receptor blockade is protective and long term detrimental timing of blocking 
strategies appears essential for outcome. The alteration in immune activation seen in 
this paper suggests a detrimental function of adenosine A2A receptor deletion and 
supports the hypothesis that the delayed injury after neonatal hypoxic ischemia is 
caused by immune activation. 
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3D representations of key immune populations plotted against the three principal components acquired by 
the Nonlinear Iterative Partial Least Squares (NIPALS) algorithm, enabling inclusion of dichotomous data like 
genotype (connected by the arrow). The genotype effect is largely expressed on component 2. Component 1 
effectively separates populations with protective (leftmost) or detrimental (to the right) effects according to prior 
knowledge reported elsewhere. Since we know that lesion size will contribute to the variance in a fashion that is 
uncorrelated to genotype and that the three components together explain 91% of the total variance in the model, 
injury size must thus be represented on component 1 or component 3. Since we found that the adenosine A2A 
deficient mice influence injury size, genotype should be represented on the component describing lesion size, 
therefore we can exclude component 3 with no loading of genotype. The immune populations that influence 
component 3 (blue dashed lines) positively is regulatory lymphocytes and myeloid derived suppressor cells 
expressing the major histocompatability complex class II and negatively influenced by costimulatory (CD86+) 
lymphocytes. However, since component 3, explaining 11% of the variance, was not influenced by adenosine A2A 
receptors, it was excluded from the manuscript. fold cross validation with expectation maximization clustering was 
used to group the populations. The cluster containing adenosine A2A deficiency (blue triangles) included regulatory 
immune populations, and the wild type (red circles) contained CD11b+ MHCII+. Proinflammatory innate populations 
were found tightly grouped in one cluster (green squares) while helper and cytotoxic Tlymphocytes were found in 
another cluster (yellow diamond). 
8.5 CAFFEINE FOR NEUROPROTECTION (PAPER IV) 
To investigate short term inhibition of adenosine receptor signaling we investigated a 
single dose caffeine 5 mg/kg given directly after hypoxic ischemia and found protection 
of the brain and improved behavioral outcome. We hypothesized that caffeine may 
modulate the inflammatory response after brain injury; yet, the alterations observed 
were minimal with transiently decreased number of activated CD8+ cytotoxic T
lymphocytes, similar to the situation in adenosine A1 receptor deficient mice. However, 
this population was only significantly different to controls after 24 hours and no 
significant difference was seen after 2 hours or two weeks. Thus, an immuno
modulatory effect was only seen when sufficiently high caffeine concentrations could 
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be expected. The protective effect of a single dose of caffeine was coherent with the 
results seen after short term adenosine A2A receptor blockade in other studies. Long 
term caffeine treatment of the mothers prior hypoxic ischemic brain injury is another 
possible administration route of caffeine for neuroprotection (Bona, Aden et al. 1995). 
When caffeine is used for apneas, repeated doses of caffeine are given over time and 
treatment correlates with less neurodevelopmental disability (Schmidt, Roberts et al. 
2007). This implicates that short term A2A receptor blockade alone cannot explain the 
entire caffeine mediated effect and the balance between adenosine A1, A2A and A2B 
receptors matters in the long run. Since electric activity and increased intracellular 
cAMP promotes neuronal survival (Goldberg and Barres 2000), there could 
hypothetically be a beneficial effect of long term caffeine due to centralnervous
system stimulation and modulation of cAMP levels. However, to our knowledge, long 
term caffeine treatment after neonatal brain injury has not been studied in respect to 
neuroprotection. Furthermore, caffeine treatment in combination with hypothermia, that 
is the treatment in clinical practice in the western world, has not been investigated. 
However, in settings where hypothermia is not available, caffeine appears, even with 
the current knowledge, as an appealing candidate for clinical neuroprotection.  
 
  Loss of MAP2 staining in neurons in three sections in the anteriorposterior direction delineates the 
infarction seen in buffered saline treated (top row) and after caffeine treatment (lower row). Each representative 
sample shown is from the brain with infarction size closest to mean in each treatment group. Especially the reduction 
of hippocampus lesions in the caffeine group (lower row) is clearly visible. 
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8.6 CONCLUSIONS 
1. We investigated TNF blockade in the neonatal period and found that 
central blockade could protect the brain against excitotoxic lesions in premature pups 
during an inflammatory insult. However, no protection against brain hypoxic ischemia 
was seen without systemic inflammation or in mice at equivalent full term age. Thus 
we conclude that age and mode of brain injury are fundamental for the effect of TNF 
blockade for neuroprotection, and major obstacles have to be resolved prior to clinical 
application of such therapy. 
2. Using flow cytometry we were able to demonstrate a long term immune 
infiltration in the brain parenchyma, months after neonatal hypoxic ischemia. 
Furthermore, splenocytes lost their tolerance against brain antigen after brain hypoxic 
ischemia and assumed a phenotype consistent with memory Tlymphocytes. Thus 
neonatal brain injury induces a long term immune response and the formation of an 
immunologic memory against brain antigens, with implications for development of 
autoimmunity and long term neurodevelopment. 
3. Adenosine A1 receptor deletion worsens the outcome after neonatal 
hypoxic ischemia and alters cerebral immune infiltration in profound ways. Mice 
deficient in adenosine A1 receptors abolished the response in regulatory 1 cells 
and cytotoxic Tlymphocytes seen in wild type mice after brain hypoxic ischemia. We 
discerned the genotype effect from lesion size elicited responses, and deduced that 
genotype caused specific alterations in immune activation. These alterations altogether 
correlated to increased brain injury in adenosine A1 receptor deficient mice. We used 
principal component analysis to discriminate between two experimentally entangled but 
uncorrelated variables, thus this methodology could be used in experimental design to 
allow more than one deviating influencing factor. 
4. Adenosine A2A receptor deletion worsens the outcome after neonatal 
hypoxic ischemia and alters cerebral immune infiltration in profound ways. 
Functionally impaired myeloid derived suppressor cells and regulatory Tlymphocytes 
were seen in adenosine A2A receptor deficient mice, paralleled by increased activation 
in cytotoxic natural killer cells and CD8+ Tlymphocytes. Moreover, we present a novel 
hypothesis that short term adenosine A2A receptor blockade offers neuroprotection 
while long term blockade is detrimental through immunological mechanisms. 
5. Caffeine treatment given as a single dose 5 kg/kg is a clinically relevant 
neuroprotective strategy targeting adenosine signaling with few and manageable 
adverse outcomes. Are we ready for a clinical study? 
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8.7 CONCLUDING REMARKS 
The technical evolution has given us access to more information and larger datasets. 
Thus, new demands on analysis and interpretation of the data have arisen. To prove a 
causational relationship in one factor is sometimes as misdirecting as a mere correlation 
(that is unable to prove causation), since nonlinear interactions and the synergistic 
effect of copious influencing factors with almost negligible individual effects often are 
disregarded. Computer based analytical approaches now seem matured to a sufficient 
level to guide us in big data analysis in biologically relevant ways. Mathematical or 
statistical coherent data is known to cause misinterpretation when not adapted to the 
biological reality. However, to acquire data of sufficient magnitude and quality is still a 
challenge. 
Further utilization of principal component analysis on experimental data has powerful 
applications and could be used in clinical trials and epidemiology. Generally speaking, 
epidemiological approaches most commonly used perform well when large populations 
are available to analyze correlations between a limited numbers of variables. However 
large populations are not always available. Thus a similar approach as in paper three 
and four could be used to investigate few subjects but plenteous variables and to 
estimate biologically relevant interactions. For example investigating one outcome in 
10000 subjects yields the same amount of information as 100 variables in 100 subjects. 
Correlation analysis handles the first situation excellently, while the latter situation with 
abundant, correlated variables will be problematic. Since principal component analysis 
does not require that the variables are uncorrelated, it is well suited for the latter 
problem. Furthermore, the identification of important variables with principal 
component analysis can be used to direct research efforts to a limited number of 
variables that experimentally could be exploited for causal relationships, for example 
by building Bayesian networks or performing a strict selection of key experiments. 
These techniques seem appropriate and necessary to address the complexity of 
adenosine receptor signaling if one aims to understand and ultimately predict its 
function: 
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Adenosine signaling 
Fundamental, although not required  
Blocking can stimulate, and activation inhibit 
Effective during extreme conditions, yet promotes normalization 
Elicits local responses, yet is ubiquitously present 
Elicits similar, and opposing effects 
Affects body and mind 
Great insight and knowledge can be gained by understanding its path. 
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ 
SVENSKA 
Syrebrist och otillräcklig blodförsörjning till hjärnan i nyföddhetsperioden är en 
allvarlig komplikation som kan ge men för livet. Målet med detta arbete har varit att 
förstå vissa aspekter av hur dessa skador uppstår och om möjligt hitta ett sätt att skydda 
hjärnan under denna avgörande period i livet. Den neonatala nyfödda hjärnan är 
normalt sett mindre känslig mot störningar i energiförsörjningen och syrebrist än den 
vuxna hjärnan, detta för att klara en förlossning. Om störningen blir så allvarlig att en 
hjärnskada uppstår kan dock även den pågående utvecklingen av den omogna hjärnan 
störas, och på så sätt orsaka dubbel skada. Samtidigt har den nyfödda hjärnan en stor 
kapacitet att kompensera för skador då den är plastisk och oskadade regioner av hjärnan 
kan ta över och utföra funktioner den vanligtvis inte har. Därför finns mycket att vinna 
på optimal behandling av asfyxiska barn med påverkad cirkulation och syresättning av 
hjärnan. Vidare har det visat sig att infektioner både kan starta för tidiga förlossningar 
och dessutom orsaka skador på hjärnans funktion. Idag är kylbehandling den enda 
specifika behandling for hjärnskador som finns tillgänglig för fullgångna barn, men för 
prematura, för tidigt födda barn, finns ingen specifik behandling alls. Stora framsteg i 
neonatalvården har ändå kunnat åstadkommas genom behandling av infektioner, 
införandet av steroider, symtomatisk akutvård samt uppföljnings och stödinsatser 
under uppväxten. 
I en musmodell av prematur hjärnskada med samtidig systemisk inflammation har vi 
visat att blockad av en inflammatorisk signalsubstans, cytokinen tumör nekros faktor 
(TNF) skyddar hjärnan. Detta skydd kunde bara ses vid samtidig inflammation. Då 
TNF förutom de immunologiska effekterna möjligtvis kan påverka både långtidsminne 
och hjärnanas utveckling och bara en andel av barnen potentiellt skulle ha någon nytta 
av behandlingen, de med systemisk inflammation, anser vi inte TNF blockad som 
neuroprotektion i nyföddhetsperioden är aktuell för klinisk applikation i en nära 
framtid. 
Då infektioner har visats vara en riskfaktor för att utveckla hjärnskador vid syrebrist 
och denna effekt medieras av immunförsvaret, har vi utvecklat en metod för att med 
flödescytometri undersöka immuncellers förmåga att infiltrera hjärnan i en neonatal 
musmodell, motsvarande den nyfödda mänskliga hjärnan. I den modellen har vi även 
kunnat testa olika tänkbara behandlingsregimer för att utvärdera dess potentiella nytta. 
Immuncellernas funktion är att skydda oss mot infektioner av bakterier, virus och 
parasiter, men de rensar även bort skadade och döende celler. Detta är normalt en bra 
funktion som skyddar mot tumörutveckling och påskyndar läkning. Vid en hjärnskada 
kan svaret under vissa omständigheter bli alltför kraftigt, varför det kan uppstå 
ytterligare förvärrad skada istället. Vi har kunnat visa i vår musmodell att denna 
immunaktivering är en långvarig process som pågår i flera månader och inte veckor 
som varit känt sedan tidigare. Vi har även visat att denna immunaktivering ger upphov 
till ett immunologiskt minne, vilket innebär att de skadliga effekterna vid upprepad 
hjärnskada kan förväntas bli mycket värre. Man kan tro att denna aktivering kan ge 
upphov till autoimmunitet senare i livet och även påverka den neuronala utvecklingen 
då det finns beskrivet att ADHD, depression och autismspektrumstörningar är 
korrelerade till ökad immunaktivering. 
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Vi har även undersökt hur adenosinreceptorer påverkar hjärnskadan och 
immunaktivering. De flesta vuxna människor intar mer eller mindre regelbundet 
centralstimulerande substanser vars effekt medieras av adenosinreceptorer. Vanligen i 
form av uppiggande drycker såsom kaffe och te, men även som läsk och energidrycker, 
alla innehållandes koffein eller teofyllin som blockerar adenosinreceptorsignalering. 
Adenosin bildas från adenosin trifosfat (ATP), som är cellens energivaluta, varför 
funktionen är nära sammankopplat med cellernas energiomsättning, något som är 
uppenbart viktigt vid syrebristorsakade hjärnskador som ju orsakas av energibrist. När 
celler dör läcker ATP ut från cellens energiförråd och ombildas snabbt till adenosin 
som binder till och aktiverar någon av de fyra adenosin receptorer som finns på 
cellväggen. Då initieras en signalkaskad som påverkar cellens beteende och överlevnad. 
Vi har använt knockoutmöss som saknar en av de fyra adenosinreceptorerna, som vi 
sedan har jämfört med möss som har alla fyra receptorerna intakta och kunde då se att 
de möss som saknade en av adenosin receptorerna hade värre skador efter av syrebrist 
orsakade hjärnskador. Vi kunde även visa att avsaknad av adenosin A1 eller A2A 
receptorer har en stor specifik påverkan på immunaktiveringen efter en hjärnskada, 
något som tyder på att adenosinsignalering har en viktig funktion för ett lagom 
aggressivt immunsvar. De förändringar vi såg i knockoutmössen var korrelerade med 
värre skador, vilket vi tolkar som att störd adenosinmedierad immunreglering påverkar 
uppkomsten av skada. 
Eftersom vi kunde se stora effekter i knockoutmössen och dessa påverkade utfallet, 
ville vi undersöka de terapeutiska möjligheter som fanns med modulering av 
adenosinsignalering, varför vi undersökte om koffein 5 mg/kg givet som en enkel dos 
efter syrebrist i hjärnan kunde skydda mot skada. Vid koffeinbehandling minskade 
skadorna och aktivering av cytotoxiska Tceller under pågående behandling sjönk 
också. Långtidseffekterna på immunaktivering efter en enda dos koffein var 
försumbara, vilket ger låg risk för långtidsbiverkningar, därmed har denna behandling 
uppenbar klinisk relevans. Biverkningsprofilen är också mycket fördelaktig när man ser 
till resultaten i väldesignade humana studier utan uppenbara felkällor. Koffein används 
dessutom redan i klinisk praxis som skydd mot andningsuppehåll hos för tidigt födda 
barn. Vi har dock inte studerat upprepade doser av koffein, vilket är vanligt i kliniken 
vid apnebehandling. Dessa resultat är ett steg emot en klinisk studie av koffein för 
neuroprotektion vid neonatal hjärnskada. Kanske är vi redo? 
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